Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease.
Latest Information Update: 28 Apr 2023
At a glance
- Drugs Resveratrol (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 11 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 08 Jun 2012 New source identified and integrated (Mayo Clinic).